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Background
Unique patterns of response have been observed with
immunotherapies. Notably, objective response and pro-
longed disease stabilization can occur after an initial
increase in tumor burden. irRC were developed to better
characterize response to immunotherapy based on data
for Ipilimumab. We previously showed that patients
with melanoma treated with the anti-PD-1 monoclonal
antibody Pembrolizumab may also experience unique
patterns of response and that conventional response cri-
teria may underestimate the therapeutic benefit of Pem-
brolizumab [1]. We updated our initial analysis to
include an additional 6 months of follow-up.
Methods
Patients from 3 melanoma cohorts treated with Pembro-
lizumab 2 mg/kg Q3W, 10 mg/kg Q3W, or 10 mg/kg
Q2W in the Phase I KEYNOTE-001 trial served as the
source population. Tumor imaging was performed every
12 weeks. Response was assessed by irRC and RECIST
v1.1 by independent central review. Patients were mana-
ged by irRC by investigator. Early and delayed pseudo-
progression were identified using centrally assessed irRC
data among patients treated with Pembrolizumab who
were followed by imaging for ≥28 weeks as of May
2014. Early pseudo-progression was defined as uncon-
firmed PD at assessment 1 (ie, week 12) and non-PD at
assessment 2. Delayed pseudo-progression was defined
as PD at any time point followed by non-PD at the next
assessment. Survival data as of May 2014 were analyzed
in all 411 patients enrolled in KEYNOTE-001.
Results
Following an incremental assessment of 6 months, there
were an additional 16 patients with ≥28 weeks of imaging
follow-up (n = 208 total), 1 additional patient who experi-
enced early pseudo-progression (n = 8 total; 3.8%), and 2
additional patients who experienced delayed pseudo-pro-
gression (n = 9 total; 4.3%). This corresponded to a 0.9%
increase in atypical responses compared with the previous
assessment. Based on analysis of best overall response in
the total population (n = 411), 2 additional patients had
PD by RECIST but CR/PR/SD by irRC (n = 53 total).
These 53 patients had favorable OS compared with the
145 patients who had PD by both criteria (Figure 1).
Conclusions
Pembrolizumab-treated patients with melanoma may
experience unique patterns of response and should be
managed accordingly. Analysis of OS suggests that con-
ventional RECIST may underestimate the benefit of
Pembrolizumab in approximately 10% of patients. These
and other data suggest that new standards for response
criteria should be considered for PD-1 inhibitors and
other immunotherapies.
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Figure 1 Kaplan-Meier Estimates of OS.
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